Furthermore, pharmacotherapies frequently utilized in these patients (β-blockers and angiotensin-converting enzyme inhibitors) have been associated with heightened anaphylaxis severity at the population level (pooled odds ratios ≈ 2.19 and 1.56, respectively), with the authors acknowledging the potential for residual confounding by underlying cardiovascular disease [16]. This evidence concerns the gene ACE and cardiovascular disorder.